| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/24/2010 | CN101677995A Use of hdac inhibitors for the treatment of melanoma |
| 03/24/2010 | CN101677993A 化合物 Compound |
| 03/24/2010 | CN101677991A hydroquinone ansamycin formulations |
| 03/24/2010 | CN101677987A solubilized formulation of docetaxel without tween 80 |
| 03/24/2010 | CN101677978A Methods of correcting imbalance between bone resorption and bone formation and kits and compositions therefor |
| 03/24/2010 | CN101677977A Combination of ER(alpha)+ ligands and histone deacetylase inhibitors for the treatment of cancer |
| 03/24/2010 | CN101677942A Intravesical apaziquone administration following transurethral resection for treating cancer |
| 03/24/2010 | CN101677606A Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food |
| 03/24/2010 | CN101676401A Scorpion peptide and preparation method |
| 03/24/2010 | CN101676306A Low molecular weight glucan and preparation method and application thereof |
| 03/24/2010 | CN101676305A Low molecular weight glucan and preparation method and application thereof |
| 03/24/2010 | CN101676304A Low-molecular-weight glucan, its preparation method and use |
| 03/24/2010 | CN101676303A Low-molecular-weight glucan, its preparation method and use |
| 03/24/2010 | CN101676302A Low molecular weight glucan and preparation method and application thereof |
| 03/24/2010 | CN101676301A Antibody for inhibitting growth of colorectal carcinoma and its use in preparation of medicament and kit |
| 03/24/2010 | CN101676297A Preparation method of sea cucumber active polypeptide under ultrasonic extraction |
| 03/24/2010 | CN101676295A Method for purifying and separating 2'-deoxidized-2',2'-difluoro nucleotide |
| 03/24/2010 | CN101676291A Rapamycin carbonate analog, pharmaceutical composition thereof, and preparation method and uses thereof |
| 03/24/2010 | CN101676286A Azaindoles useful as inhibitors of JAK and other protein kinases |
| 03/24/2010 | CN101676267A N-4-(1-cyan cyclopentyl) phenyl-2-(4-picolyl) amidogen-3-pyridinecarboxamide salt |
| 03/24/2010 | CN101676266A Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same |
| 03/24/2010 | CN101675995A 10-hydroxycamptothecinreagent-delivery lipid ultrasound microbubble agent and its preparation method |
| 03/24/2010 | CN101675994A Therapy vaccine preparation |
| 03/24/2010 | CN101675993A melan-a peptide analogue-virus-like-particle conjugates |
| 03/24/2010 | CN101675988A A middle-Jiao-warming, cold-dispelling, stasis-dissolving and toxin-dispelling traditional Chinese medicine composition |
| 03/24/2010 | CN101675980A Traditional Chinese medicine composition for treating cancer |
| 03/24/2010 | CN101675978A Anticancer mixture, green plant preparation for treating cancer |
| 03/24/2010 | CN101675973A Heat-clearing and detoxifying phlegm-reducing and masses-resolving traditional Chinese medicine composition |
| 03/24/2010 | CN101675961A A medicinal preparation for treating breast cancer and preparation method thereof |
| 03/24/2010 | CN101675938A Preparation method and use of a novel peptide type immunizing agent whole-egg protein peptide |
| 03/24/2010 | CN101675931A New uses of acyl chloride and sulfonyl chloride derivatives in preparing anti-tumor drug |
| 03/24/2010 | CN101675930A Pharmaceutical composition for treating hyperplasia diseases |
| 03/24/2010 | CN101675927A therapeutic molecules and methods-1 |
| 03/24/2010 | CN101675924A Application of ascaridol in preparing medicine for preventing helicobacter pylori and treating disease caused by helicobacter pylori |
| 03/24/2010 | CN101675922A Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use |
| 03/24/2010 | CN101675918A Self-emulsifying micro-emulsion composition, preparation method and usage thereof |
| 03/24/2010 | CN100595281C Adenocarcinoma marker and its uses |
| 03/24/2010 | CN100595211C Angiopoietin-2 specific binding agents |
| 03/24/2010 | CN100595200C Compound of dehydrogenated cavidine group and application in medication |
| 03/24/2010 | CN100594938C Pulullan polysaccharide carrier material having the function of targeting therapy of cancer |
| 03/24/2010 | CN100594935C Antibodies that immunospecifically bind to trail receptors |
| 03/24/2010 | CN100594930C Medicinal composition using anterior pituitary adrenal cortical extract as main component, and its preparation method and use |
| 03/24/2010 | CN100594903C HCV inhibiting bi-cyclic pyrimidines |
| 03/24/2010 | CN100594902C Nano micelle preparation of Catharanthus roseus alkaloids antineoplastic drugs with coating of phospholipid derived from polyethylene glycol |
| 03/24/2010 | CN100594900C Application of alkaloid compounds in preparing antineoplastic medicaments |
| 03/24/2010 | CN100594896C Application of zedoary root cyclic diolefine in preparing medicament for treating tumour disease |
| 03/24/2010 | CN100594887C Anticancer slow release injection comprising tetrazole violet and potentiating agent thereof |
| 03/24/2010 | CN100594886C Anticancer slow release agent loading both newborn blood vessel and tetrazole violet |
| 03/24/2010 | CN100594884C Recombination human interferon injection |
| 03/23/2010 | US7683185 6-(4-Dimethylamino-phenylsulfanyl)-hexa-2,4-dienoic acid methyl ester; stimulating hematopoietic cells ex vivo |
| 03/23/2010 | US7683164 Nucleic acid derivatives |
| 03/23/2010 | US7683097 Topoisomerase inhibitors |
| 03/23/2010 | US7683094 2-(2-((2R)-2-heptylaminomethyl-5-oxopyrrolidin-1-yl)ethylthio)-1,3-thiazole-4-carboxylic acid; EP2 and/or EP4 receptor agonist; immune disease; antiallergens; alopecia; dysmenorrhea; erectile dysfuncction; antiarthritic agents; liver, respiratory, vascular, urogenital disorder |
| 03/23/2010 | US7683078 Neuronal disorders, autoimmune diseases, cancer, cardiovascular diseases; such as 4-Chloro-N-{5-[1-(4-trifluoromethyl-benzyl)-piperidin-3-ylsulfamoyl]-25 thiophen-2-ylmethyl)-benzamide |
| 03/23/2010 | US7683062 of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide; dysfunction of peripheral-type benzodiazepine receptors; anticarcinogenic, antiinflammatory agent, neurodegenerative diseases; stresses, arthritis; improved bioavailability, solubility, storage stability |
| 03/23/2010 | US7683060 3-[1-(4-Methoxyphenyl)cyclopropyl]-6-phenyl[1,2,4]triazolo[4,3-b][1,2,4]triazine; cancer and other diseases related to the dysregulation of kinase pathways; c-Met inhibitors |
| 03/23/2010 | US7683038 Such as gellan, carboxymethylcellulose, pectic acid, pectin and hyaluronic acid derivativesl; for use in the pharmaceutical, biomedical, surgical and healthcare fields |
| 03/23/2010 | US7683034 Use of enzyme inhibitors of aminopeptidase N and/or dipeptidylpeptidase IV |
| 03/23/2010 | US7682638 Use of hederagenin 3-O-α-L-rhamnopyranosyl(1-2)-[β-D-glucopyranosyl(1-4)]-α-L-arabinopyranoside or an extract from pulsatillae radix containing the same as a therapeutic agent for solid tumors |
| 03/23/2010 | US7682635 Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds |
| 03/23/2010 | US7682630 Antitumor agent that forms polymeric micelle complex of low molecule weight antitumor agent with styrene maleic acid copolymer; formed in polymeric micelle complex by intermolecular bonding or mutual interaction between styrene maleic acid copolymer and antitumor agent; reduced side effects |
| 03/23/2010 | US7682623 Pharmaceutical composition for topical application |
| 03/23/2010 | US7682612 Chronic Lymphocytic Leukemia (CLL) is treated with antibodies directed against the CD20 antigen; rituximab; chemotherapy |
| 03/23/2010 | US7682607 Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| 03/23/2010 | US7682387 Drug-delivery endovascular stent and method for treating restenosis |
| 03/23/2010 | CA2519801C Use of 5-substituted nucleosides |
| 03/23/2010 | CA2460177C 3-substituted-4-pyrimidone derivatives |
| 03/23/2010 | CA2404278C Naphthalimide compositions and uses thereof |
| 03/23/2010 | CA2399405C 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 03/23/2010 | CA2397594C Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one |
| 03/23/2010 | CA2396702C N,o-amidomalonate platinum complexes |
| 03/23/2010 | CA2392709C Polyhydroxylated aromatic compounds for the treatment of amyloidosis |
| 03/23/2010 | CA2390317C Product inhibiting transduction of g heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 03/23/2010 | CA2389767C Quinazoline derivatives as vegf inhibitors |
| 03/23/2010 | CA2380951C Pharmaceutical compositions for oral and topical administration |
| 03/23/2010 | CA2378052C Use of ginkgo extract |
| 03/23/2010 | CA2305312C Mammalian genes involved in viral infection and tumor suppression |
| 03/23/2010 | CA2209124C Antitumor agent effect enhancer containing il-6 antagonist |
| 03/23/2010 | CA2203655C Tumor necrosis factor-gamma |
| 03/23/2010 | CA2194797C Nucleic acid containing composition, preparation and uses of same |
| 03/23/2010 | CA2149818C Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders |
| 03/18/2010 | WO2010030983A2 Pyrazole carboxamide inhibitors of factor xa |
| 03/18/2010 | WO2010030980A2 Akt and clusterin as biomarkers of chemotherapeutic responsiveness |
| 03/18/2010 | WO2010030967A1 4-aryloxyquinolin-2(1h)-ones as mtor kinase and pi3 kinase inhibitors, for use as anti-cancer agents |
| 03/18/2010 | WO2010030781A2 Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer |
| 03/18/2010 | WO2010030727A1 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 03/18/2010 | WO2010030687A1 Monoclonal antibodies specific for pancreatic neoplasia cells |
| 03/18/2010 | WO2010030666A2 Elimination of a contaminating non-human sialic acid by metabolic competition |
| 03/18/2010 | WO2010030598A2 Pharmaceutical formulations comprising pemetrexed |
| 03/18/2010 | WO2010030012A1 ESTERIFIED α-GALACTOSYLCERAMIDE |
| 03/18/2010 | WO2010030002A1 Cell capable of expressing exogenous gitr ligand |
| 03/18/2010 | WO2010029577A2 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers |
| 03/18/2010 | WO2010029232A1 Metalloporphyrin derivatives, nanoparticles comprising the same, and use thereof for photodynamic therapy |
| 03/18/2010 | WO2010029185A1 Oligosaccharide compounds for use in mobilising stem cells |
| 03/18/2010 | WO2010029158A1 Aplidine in the treatment of chronic myeloproliferative disorders |
| 03/18/2010 | WO2010029119A1 Novel imidazolidine compounds as androgen receptor modulators |
| 03/18/2010 | WO2010029082A1 Organic compounds |
| 03/18/2010 | WO2010028862A1 Pyrrolidin-2-ones as hdm2 ligands |
| 03/18/2010 | WO2010028858A1 Use of cis-imidazolines, particularly nutlins, for treating chemo-resistant cancer diseases |
| 03/18/2010 | WO2010028781A1 8- and 6,8-substituted-2'-deoxyguanosines and uses thereof |